SELLAS Life Sciences Group, Inc. Stock Split Ratio
SELLAS Life Sciences Group, Inc. (SLS) had Stock Split Ratio of 2.00% as of 2019-11-07, per its 10-Q filed 2020-11-13.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2020-11-13
- SELLAS Life Sciences Group, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2017 was 3.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|
| 2019-11-07 | 2.00% 10-Q · filed 2020-11-13 | |
| 2019-11-06 | 2.00% 10-K · filed 2020-03-13 | |
| 2017-12-31 | 3.00% 10-K · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |